
Venture capital · Early stage
VESALIUS BIOCAPITAL IV Partners Sarl
Luxembourg-based venture capital manager running its fourth fund, which backs European life sciences businesses spanning biopharma, devices, diagnostics and digital health.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is VESALIUS BIOCAPITAL IV Partners Sarl right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (ESMA register).
Latest investments
Rounds VESALIUS BIOCAPITAL IV Partners Sarl joined, from press and the firm’s own posts.
Every round VESALIUS BIOCAPITAL IV Partners Sarl joined
Round sizes, VESALIUS BIOCAPITAL IV Partners Sarl’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company VESALIUS BIOCAPITAL IV Partners Sarl backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet VESALIUS BIOCAPITAL IV Partners Sarl
Events where VESALIUS BIOCAPITAL IV Partners Sarl’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
VESALIUS BIOCAPITAL IV Partners Sarl is based in Luxembourg. It also has an office in Contern.
2 fund vehicles are on public registers (ESMA register), including VESALIUS BIOCAPITAL IV INVESTMENTS S.A., SICAR-compartiment virtuel and VESALIUS BIOCAPITAL IV S.C.A., SICAR-compartiment virtuel.
Stages: Early stage. Sectors: Life sciences, Health tech, Biotech, Medtech. From the firm’s own website.
Backs European biopharma and healthtech companies that tackle unmet medical needs and are protected by solid IP. Builds a diversified book across therapeutic areas, development stages, technologies and countries, works hands-on with entrepreneurs, funds them step by step, keeps reserves for follow-ons and usually leads or co-leads rounds. From the firm’s own website.
€10M to €15M per investment, according to the firm’s own website.
VESALIUS BIOCAPITAL IV Partners Sarl lists 6 portfolio companies on its website, including Nutrium, ENYO Pharma, Inflammatix, HepaRegeniX and inHEART.
Firms whose websites list some of the same companies include Cleverage Capital, Khosla Ventures and Marram Ventures.
Know before VESALIUS BIOCAPITAL IV Partners Sarl’s next round is announced.
PRO tracks VESALIUS BIOCAPITAL IV Partners Sarl’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.